Loading stock data…
Atea Pharmaceuticals (AVIR)
$4.61+0.12 (+2.67%)
After Hours$4.61+0.00 (+0.00%)· Last close Jun 29
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atea Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.61 with a market capitalization of $350M. Wall Street consensus targets $8.67 (3 analysts), implying a +88.0% move over the next 12 months. The stock is currently 29% below its 52-week high of $6.45, remaining 11.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +88.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.01M↑ | -$54.93M↓ | -$45.57M↓ | -$41.34M↓ | -$39.04M |
| Net Income | -$45.44M↓ | -$44.87M↓ | -$42.05M↓ | -$37.16M↓ | -$34.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$350.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.53%
Volume
Today's trading volume
320,355
Recent News
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks
Over the last 7 days, the market has risen 1.1%, with a notable 29% increase over the past year and earnings projected to grow by 17% annually. While penny stocks might seem like a term from bygone market eras, they continue to offer intriguing opportunities for investors seeking affordability and growth potential in smaller or newer companies. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term success amidst current market...
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.